| Literature DB >> 22536488 |
Akl C Fahed1, Abdul-Karim M El-Hage-Sleiman, Theresa I Farhat, Georges M Nemer.
Abstract
The Middle East and North Africa (MENA) region suffers a drastic change from a traditional diet to an industrialized diet. This has led to an unparalleled increase in the prevalence of chronic diseases. This review discusses the role of nutritional genomics, or the dietary signature, in these dietary and disease changes in the MENA. The diet-genetics-disease relation is discussed in detail. Selected disease categories in the MENA are discussed starting with a review of their epidemiology in the different MENA countries, followed by an examination of the known genetic factors that have been reported in the disease discussed, whether inside or outside the MENA. Several diet-genetics-disease relationships in the MENA may be contributing to the increased prevalence of civilization disorders of metabolism and micronutrient deficiencies. Future research in the field of nutritional genomics in the MENA is needed to better define these relationships.Entities:
Year: 2012 PMID: 22536488 PMCID: PMC3321453 DOI: 10.1155/2012/109037
Source DB: PubMed Journal: J Nutr Metab ISSN: 2090-0724
Figure 1Map of the Middle East and North Africa (MENA) region. The MENA region includes countries such as Algeria, Armenia, and Turkey, that are not members of the WHO Eastern Mediterranean Region (EMR) that is referred to in the literature.
Figure 2Increasing prevalence of diabetes mellitus in the MENA. (a) General increase in reported prevalence (%) of Type 2 Diabetes Mellitus in the MENA between the years 2000 and 2010. Numbers are reported as approximated by the International Diabetes Federation [12–15]. The expected 2-fold increase for the year 2030 is approximated based on demographic parameters, without accounting for changes in age strata or other risk factors [16]. (b) Overall growth in annual incidence (per 100,000) of Type 1 diabetes mellitus in children younger than 14 years old in the MENA. Numbers are estimations by the International Diabetes Federation based on various years between 1986 and 2000 [12–15].
Figure 3Increasing prevalence of obesity in the MENA. Prevalence (%) of obesity increased in both men and women in countries of the MENA between 2004 and 2008. Numbers are WHO estimates in World Health Statistics of 2005 and 2011. Totals of men and women are integrated for purposes of comparative illustration and do not represent adjusted arithmetic total prevalences. Obesity was defined as body mass index (BMI) ≥30 Kg/m2. Obesity data about Jordanian men in 2004 are not available, but prevalence was estimated to be less than that of women [17, 18]. KSA: Kingdom of Saudi Arabia; UAE: United Arab Emirates.
Figure 4Expected overall increase in mortality due to cardiovascular diseases in the MENA [19]. CAD: Coronary Artery Disease; CVE: Cerebrovascular Event.
Rates of cardiovascular disease, hypertension, and the metabolic syndrome in MENA countries from different studies.
| Coronary artery disease (CAD) | |||
|
| |||
| Iran | Age-adjusted prevalence (%) | 12.7 | Nabipour et al. [ |
| Jordan | Prevalence (%) | 5.9 | Nsour et al. [ |
|
| |||
| Saudi Arabia, | |||
| (rural) | Prevalence (%) | 4.0 | Al-Nozha et al. [ |
| (urban) | Prevalence (%) | 6.2 | |
| (overall) | Prevalence (%) | 5.5 | |
|
| |||
| Tunisia | Prevalence (%), [men] | 12.5 | Ben Romdhane et al. [ |
| Prevalence (%), [women] | 20.6 | ||
|
| |||
| Cerebrovascular Accidents | |||
|
| |||
| Bahrain | Age-adjusted incidence (per 100,000) | 96.2 | Al-Jishi and Mohan [ |
| Iran | Age-adjusted incidence (per 100,000) | 61.5 | Ahangar et al. [ |
| Kuwait | Age-adjusted incidence (per 100,000) | 92.2 | Abdul-Ghaffar et al. [ |
| Libya | Age-adjusted incidence (per 100,000) | 114.2 | Radhakrishnan et al. [ |
| Palestine | Age-adjusted incidence (per 100,000) | 62.7 | Sweileh et al. [ |
| Qatar | Age-adjusted incidence (per 100,000) | 123.7 | Hamad et al. [ |
| Saudi Arabia | Age-adjusted incidence (per 100,000) | 38.5 | Al-Rajeh et al. [ |
|
| |||
| Hypertension (HTN) | |||
|
| |||
| Algeria | Prevalence (%), [Age > 25] | 36.2 | Yahia-Berrouiguet et al. [ |
| Bahrain | Prevalence (%), [Age > 20] | 42.1 | Al-Zurba [ |
|
| |||
| Egypt | Age-adjusted prevalence (%) | 27.4 | Ibrahim et al. [ |
| Prevalence (%), [Age > 25] | 26.3 | Galal [ | |
|
| |||
| Iran | Prevalence (%), [Age > 19] | 25.6 | Sarraf-Zadegan et al. [ |
| Prevalence (%), [Age: 30–55] | 23.0 | Haghdoost et al. [ | |
| Prevalence (%), [Age > 55] | 49.5 | ||
|
| |||
| Iraq | Prevalence (%), [Age > 20] | 19.3 | WHO: STEPwise, [ |
| Jordan | Prevalence (%), [Age > 18] | 30.2 | Zindah et al. [ |
| Lebanon | Prevalence (%), [Age: 18–65] | 31.2 | Sibai et al. [ |
| Morocco | Prevalence (%), [Age > 20] | 33.6 | Tazi et al. [ |
| Oman | Prevalence (%), [Age > 20] | 21.5 | Hasab et al. [ |
|
| |||
| Palestine (WB), | |||
| (rural) | Prevalence (%), [Age: 30–65] | 25.4 | Abdul-Rahim et al. [ |
| (urban) | Prevalence (%), [Age: 30–65] | 21.5 | |
|
| |||
| Qatar | Prevalence (%), [Age: 25–65] | 32.1 | Bener et al. [ |
| Saudi Arabia | Prevalence (%), [Age: 30–70] | 26.1 | Al-Nozha et al. [ |
| Sudan | Prevalence (%), [Age: 25–64] | 23.6 | WHO: STEPwise, [ |
| Syria | Prevalence (%), [Age: 18–65] | 40.6 | Maziak et al. [ |
| Turkey | Age-adjusted prevalence (%) | 25.7 | Sonmez et al. [ |
| UAE | Prevalence (%), [Age > 20] | 20.8 | Baynouna et al. [ |
| Yemen | Prevalence (%), [Age > 35] | 26.0 | Gunaid and Assabri [ |
| Middle East | Prevalence (%), (overall) | 21.7 | Motlagh et al. [ |
|
| |||
| Metabolic Syndrome | |||
|
| |||
| Algeria | Prevalence (%), [Age > 20] | 17.4 | Mehio Sibai et al. [ |
| Iran | Prevalence (%), [Age > 19] | 23.3 | Mehio Sibai et al. [ |
| Jordan | Prevalence (%), [Age > 18] | 36.3 | Khader et al. [ |
| Kuwait | Prevalence (%), [Age > 20] | 24.8 | Al Rashdan and Al Nesef [ |
| Lebanon | Prevalence (%), [Age: 18–65] | 25.4 | Mehio Sibai et al. [ |
| Morocco, (rural) | Prevalence (%), [women] | 16.3 | Rguibi and Belahsen [ |
|
| |||
| Oman, | |||
| (overall) | Prevalence (%), [Age > 20] | 21.0 | Al-Lawati et al. [ |
| (Nizwa) | Age adjusted prevalence (%) | 8.0 | Al-Lawati et al. [ |
|
| |||
| Palestine (WB) | Prevalence (%), [Age: 30–65] | 17.0 | Abdul-Rahim et al. [ |
|
| |||
| Qatar | Prevalence (%), [Age > 20] | 27.7 | Musallam et al. [ |
| Age adjusted prevalence (%) | 26.5 | Bener et al. [ | |
|
| |||
| Saudi Arabia | Age adjusted prevalence (%) | 39.3 | Al-Nozha et al. [ |
| Tunisia | Prevalence (%), [Age > 20] | 16.3 | Bouguerra et al. [ |
| UAE | Prevalence (%) | 39.6 | Malik and Razig [ |
Nonadjusted rates from different studies are not valid for comparison but displayed to present the burden of the morbidities. HTN is defined as BP > 140/90 or use of antihypertensive medications. Metabolic Syndrome definition is based on Adult Treatment Panel III, except for Palestine and Tunisia where, respectively, WHO criteria and hypercholesterolemia (Total Cholesterol ≥5.2 mmol/l) instead of low HDL cholesterol were used. UAE: United Arab Emirates; WB: West Bank [103, 113–116].
Rates of Vitamin D deficiency and iron deficiency in MENA countries from different studies.
| Vitamin D deficiency (VDD) | |||
|
| |||
| Iran | Prevalence (%), [girls], [adolescent] | Up to 70 | Moussavi et al. [ |
|
| |||
| Jordan | Prevalence (%), | ||
| [adult females] | 37.3 | Batieha et al. [ | |
| [adult males] | 5.1 | ||
|
| |||
| Lebanon | Prevalence (%), | ||
| [girls] | 32 | El-Hajj Fuleihan et al. [ | |
| [boys] | 9–12 | ||
|
| |||
| Morocco (Rabat) | Prevalence (%), [women] | 91 | Arabi et al. [ |
| Saudi Arabia | Prevalence (%), [girls], [adolescent] | Up to 80 | Siddiqui and Kamfar [ |
| Tunisia (Ariana) | Prevalence (%), [women], [Age: 20–60] | 47.6 | Arabi et al. [ |
|
| |||
| Turkey (Ankara) | Prevalence (%), | ||
| [mothers] | 46 | Arabi et al. [ | |
| [newborns] | 80 | ||
|
| |||
| Iron deficiency | |||
|
| |||
| Arab Gulf countries | Prevalence (%), | ||
| [children], [preschool age] | 20–67 | Musaiger [ | |
| [children], [school age] | 12.6–50 | ||
| [pregnant women] | 22.7–54 | ||
|
| |||
| Bahrain | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 48 | Bagchi [ | |
| [women], [Age: 15–49] | 37.3 | ||
|
| |||
| Egypt | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 25 | Bagchi [ | |
| [women], [Age: 15–49] | 11 | ||
|
| |||
| Iran | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 15–30 | Bagchi [ | |
| [women], [Age: 15–49] | 33.4 | ||
|
| |||
| Jordan | Prevalence (%),[children], [school age] | 20 | Bagchi [ |
| Prevalence (%), [women], [Age: 15–49] | 28 | ||
|
| |||
| Lebanon | Prevalence (%), [children], [Age: 6–59 months] | 23 | Bagchi [ |
|
| |||
| Morocco | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 35 | Bagchi [ | |
| [women], [Age: 15–49] | 30.1 | ||
|
| |||
| Oman | Prevalence (%), | ||
| [children], [Age: 5–14] | 41 | Bagchi [ | |
| [women], [Age: 15–49] | 40 | ||
|
| |||
| Pakistan | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 60 | Bagchi [ | |
| [women], [Age: 15–49] | 30 | ||
|
| |||
| Palestine | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 53 | Bagchi [ | |
| [women], [Age: 15–49] | 36.2 | ||
|
| |||
| Saudi Arabia | Prevalence (%), [children], [preschool age] | 17 | Bagchi [ |
|
| |||
| Syria | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 23 | Bagchi [ | |
| [women], [Age: 15–49] | 40.8 | ||
|
| |||
| UAE | Prevalence (%), | ||
| [children], [Age: 6–59 months] | 34 | Bagchi [ | |
| [pregnant women] | 14 | ||
|
| |||
| Yemen | Prevalence (%), [children], [preschool age] | 70 | Bagchi [ |
Different limits of blood levels define VDD, ranging from insufficiency to severe deficiency, similar for Iron deficiency. UAE: United Arab Emirates [147, 150].
Figure 5The dietary signature. The biologically inherited DNA genome accumulates DNA sequence variations over generations. Epigenetic profiles determine which parts of it are to be transcribed. Once transcribed to RNA, it matures into different mature RNA outcomes depending on the post-transcriptional regulators. Among the effects of the environment on DNA sequence variations, epigenetic profiles, and post-transcriptional regulators, the effect of diet is studied in nutrigenomics. After translation, and under the impact of dietary status surrounding the primarily translated proteome, the final set of functional proteins, activated pathways, and subsequent metabolites constitutes the functional Gene Product. The gene product is only potentially functional towards a certain phenotypic outcome. The downstream end result of health status depends greatly on what nutrients are fed into the systemic machine of gene products. The functional gene product is the end-point in nutrigenomics and the starting point in nutrigenetics. It is a marker of the phenotypic outcome: expression of disease and prognosis. Phenotype may dictate the lifestyle choices available to a certain individual, including taste preferences, which are also delineated by culturally inherited customs and habits. In their turn, lifestyle choices including dietary habits determine environmental exposures. Furthermore, civilization diseases have been hidden for a long period of time due to the sociocultural inheritance of adequately evolved matching lifestyle preferences and diet choices that have been masking a biologically inherited limited gene pool. The genes being in status quo, in presence of a nutritional transition, the rates of civilization diseases are on the rise because of the loss of the protective adequacy of the diet. This highlights the presence of hidden genes, the phenotypic expression of which can be masked by a specific nutritional state, such as that corresponding to the Mediterranean diet, as more increasingly being recommended recently in the literature. However this cannot be answered if sequence variations and specific SNPs affecting nutritional needs are not tested for in the specific populations.
Figure 6Vitamin D pathway and sites of interaction with dietary factors. Cutaneous or dietary vitamin D is hydroxylated in the liver to form 25-hydroxyvitamin D (1,2) and in the kidney to form 1α,25-dihydroxyvitamin D (3). 1α,25-dihydroxyvitamin D binds to VDR (4), the 1α,25-dihydroxyvitamin D ligand promotes VDR-RXR heterodimerization (5), and the complex binds to VDRE to mediate transcriptional regulation of target genes (6). The concept of gene-diet interaction is described in the vitamin D pathway by the different polymorphisms in the VDR gene (a) and the dietary regulation of CYP24A1 enzyme (b).